3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Sarcoma
1
CNS
1
Conditions
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
147
Radiotherapy
91
Cyclophosphamide
53
Magnetic Resonance Spectroscopy
43
Radiation
42
Bevacizumab
38
Irinotecan
34
Filgrastim
29
Radiosurgery
27
Specimen Handling
25
Nivolumab
25
Carboplatin
24
Topotecan
23
Etoposide
22
fludarabine
20
Surgical Procedures, Operative
20
pembrolizumab
19
Vorinostat
18
Vincristine
18
Melphalan
17
Granulocyte Colony-Stimulating Factor
17
sargramostim
15
Peripheral Blood Stem Cell Transplantation
14
Ipilimumab
14
Drug Therapy
13
temsirolimus
12
Sirolimus
12
Radiotherapy, Intensity-Modulated
12
O(6)-benzylguanine
12
Everolimus
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
interferon gamma-1b
×
CNS
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled